VSIR expression was significantly lower in favorable-risk AML (i.e., RUNX1-RUNX1T1 [t(8;21)], PML-RARα [t(15;17)]) than in intermediate and poor-risk AML (i.e., intermediate risk: NPM1 mutation, normal karyotype etc.; poor risk: complex karyotype, monosomy [del(5), del(7)], etc.)(Supplemental Figure 1D). This evidence concerns the gene VSIR and acute myeloid leukemia.